Allergic rhinoconjunctivitis with/without asthma in cat dander/dust mite/pollen allergic patients.
Conditions
Interventions
Group 1: 3-month intake of the immunoBON/holo-BLG lozenge
Sponsors
Bencard Allergy
Eligibility
Sex/Gender
All
Age
3 Years to No maximum
Inclusion criteria
Inclusion criteria: IgE-mediated allergic rhinoconjunctivitis with or without asthma against birch pollen OR house dust mites (HSM) and/or animal epithelia for at least one year (all degrees of severity), confirmed by prick test or by means of corresponding IgE detection in serum (co-sensitizations without clinical relevance are allowed). - At the time of inclusion, no indication for allergen-specific immunotherapy (AIT) given or AIT not desired by the patient. - Age from 3 years under the condition that the tablets can be reliably sucked - Written consent for data collection
Exclusion criteria
Exclusion criteria: - Intolerance of milk protein - Diseases of the gastrointestinal tract (e.g. eosinophilic esophagitis) and/or serious diseases which, in the opinion of the investigator, constitute a contraindication to the use of immunoBON - Medical conditions associated with an increased risk of aspiration - Ongoing performance of AIT - Completed AIT for the dominant allergen to be documented within the last 12 months. - Lactose intolerance to an extent which, in the opinion of the attending physician, constitutes a contraindication to the use of immunoBON
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rhinoconjunctivitis Score, Combined symptom and medication score (CSMS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability and Adherence | — |
Countries
Germany
Contacts
Public ContactRalph Mösges
ClinCompetence Cologne GmbH
Outcome results
None listed